Luc Laberge1,2,3,4,5, Benjamin Gallais6,7,8,9, Julie Auclair6, Yves Dauvilliers10, Jean Mathieu7,8,9, Cynthia Gagnon7,8,9. 1. ÉCOBES-Recherche et Transfert, Cégep de Jonquière, 2505, Rue Saint Hubert, Jonquière, QC, G7X 7W2, Canada. luclaberge@cegepjonquiere.ca. 2. Département des Sciences de la Santé, Université du Québec à Chicoutimi, 555, Boul. de l'Université, Chicoutimi, QC, G7H 2B1, Canada. luclaberge@cegepjonquiere.ca. 3. Faculté de Médecine et des Sciences de la Santé, École de Réadaptation, Université de Sherbrooke, Sherbrooke, QC, Canada. luclaberge@cegepjonquiere.ca. 4. Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN), Centre Intégré Universitaire de Santé et de services Sociaux du Saguenay-Lac-St-Jean, Jonquière, QC, Canada. luclaberge@cegepjonquiere.ca. 5. Centre de Recherche Charles-Le-Moyne, Centre Intégré Universitaire du Saguenay-Lac-St-Jean sur les Innovations en Santé, Université de Sherbrooke, Jonquière, QC, Canada. luclaberge@cegepjonquiere.ca. 6. ÉCOBES-Recherche et Transfert, Cégep de Jonquière, 2505, Rue Saint Hubert, Jonquière, QC, G7X 7W2, Canada. 7. Faculté de Médecine et des Sciences de la Santé, École de Réadaptation, Université de Sherbrooke, Sherbrooke, QC, Canada. 8. Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN), Centre Intégré Universitaire de Santé et de services Sociaux du Saguenay-Lac-St-Jean, Jonquière, QC, Canada. 9. Centre de Recherche Charles-Le-Moyne, Centre Intégré Universitaire du Saguenay-Lac-St-Jean sur les Innovations en Santé, Université de Sherbrooke, Jonquière, QC, Canada. 10. Département de Neurologie, Hôpital Gui-de-Chauliac, INSERM U1061, 80 Avenue Augustin Fliche, 34295, Montpellier Cedex 5, France.
Abstract
OBJECTIVE: Daytime sleepiness and fatigue are prominent symptoms of myotonic dystrophy type I (DM1) that exact a heavy toll on patients' quality of life, but information is scarce on their predictive factors. This study aimed to determine factors that may influence levels of daytime sleepiness and fatigue in a large cohort of DM1 patients followed for 9 years. METHODS: This study included 115 patients with DM1 at baseline (Time 1, T1) and at Time 2 (T2) who were questioned for daytime sleepiness, fatigue, history of depression, psychological distress, pain, hypothyroidism, and sleep habits. Also, their muscular impairment and intellectual quotient were evaluated. Regression models were used to identify correlates of daytime sleepiness and fatigue while controlling for time effect. RESULTS: Both daytime sleepiness and fatigue increased between T1 and T2, but their rate of change are higher when CTG repeat number is higher (p < 0.05). Also, higher psychological distress level is associated with higher daytime sleepiness and fatigue levels both at T1 and T2 (p < 0.01). Moreover, patients with a history of depression report higher daytime sleepiness levels both at T1 and T2 (p < 0.05). In addition, patients with higher fatigue levels both at T1 and T2 have more severe muscular impairment (p < 0.01) and report a longer habitual sleep duration (p < 0.05). Finally, a higher BMI and a history of hypothyroidism predict higher daytime sleepiness levels at T2 (p < 0.05). CONCLUSION: This study identified potentially modifiable risk factors of future daytime sleepiness and fatigue in DM1 patients, including BMI, psychological distress, hypothyroidism, and sleep habits.
OBJECTIVE: Daytime sleepiness and fatigue are prominent symptoms of myotonic dystrophy type I (DM1) that exact a heavy toll on patients' quality of life, but information is scarce on their predictive factors. This study aimed to determine factors that may influence levels of daytime sleepiness and fatigue in a large cohort of DM1patients followed for 9 years. METHODS: This study included 115 patients with DM1 at baseline (Time 1, T1) and at Time 2 (T2) who were questioned for daytime sleepiness, fatigue, history of depression, psychological distress, pain, hypothyroidism, and sleep habits. Also, their muscular impairment and intellectual quotient were evaluated. Regression models were used to identify correlates of daytime sleepiness and fatigue while controlling for time effect. RESULTS: Both daytime sleepiness and fatigue increased between T1 and T2, but their rate of change are higher when CTG repeat number is higher (p < 0.05). Also, higher psychological distress level is associated with higher daytime sleepiness and fatigue levels both at T1 and T2 (p < 0.01). Moreover, patients with a history of depression report higher daytime sleepiness levels both at T1 and T2 (p < 0.05). In addition, patients with higher fatigue levels both at T1 and T2 have more severe muscular impairment (p < 0.01) and report a longer habitual sleep duration (p < 0.05). Finally, a higher BMI and a history of hypothyroidism predict higher daytime sleepiness levels at T2 (p < 0.05). CONCLUSION: This study identified potentially modifiable risk factors of future daytime sleepiness and fatigue in DM1patients, including BMI, psychological distress, hypothyroidism, and sleep habits.
Authors: Cynthia Gagnon; Chad Heatwole; Luc J Hébert; Jean-Yves Hogrel; Luc Laberge; Mario Leone; Giovanni Meola; Louis Richer; Valeria Sansone; Marie Kierkegaard Journal: J Neuromuscul Dis Date: 2018
Authors: Mieke C E Hermans; Ingemar S J Merkies; Luc Laberge; Eveline W Blom; Alan Tennant; Catharina G Faber Journal: Muscle Nerve Date: 2012-10-05 Impact factor: 3.217
Authors: Carla Gliem; Martina Minnerop; Sandra Roeske; Hanna Gärtner; Jan-Christoph Schoene-Bake; Sandra Adler; Juri-Alexander Witt; Felix Hoffstaedter; Christiane Schneider-Gold; Regina C Betz; Christoph Helmstaedter; Marc Tittgemeyer; Katrin Amunts; Thomas Klockgether; Bernd Weber; Cornelia Kornblum Journal: PLoS One Date: 2019-03-07 Impact factor: 3.240
Authors: P Melacini; C Villanova; E Menegazzo; G Novelli; G Danieli; G Rizzoli; G Fasoli; C Angelini; G Buja; M Miorelli Journal: J Am Coll Cardiol Date: 1995-01 Impact factor: 24.094
Authors: Ellen van der Plas; Timothy R Koscik; Vincent Magnotta; Sarah A Cumming; Darren Monckton; Laurie Gutmann; Peggy Nopoulos Journal: Neurol Genet Date: 2021-03-18
Authors: Kamyra S Edokpolor; Anwesha Banerjee; Zachary T McEachin; Jingsheng Gu; Adam Kosti; Juan D Arboleda; Paul S García; Eric T Wang; Gary J Bassell Journal: eNeuro Date: 2022-10-10
Authors: Jacob N Miller; Alison Kruger; David J Moser; Laurie Gutmann; Ellen van der Plas; Timothy R Koscik; Sarah A Cumming; Darren G Monckton; Peggy C Nopoulos Journal: Front Neurol Date: 2021-07-01 Impact factor: 4.003